{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:37:53Z","timestamp":1788435473595,"version":"build-2803163510"},"reference-count":170,"publisher":"Elsevier","isbn-type":[{"value":"9780128239223","type":"print"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/bs.acc.2020.04.004","type":"book-chapter","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T07:17:52Z","timestamp":1590218272000},"page":"171-204","source":"Crossref","is-referenced-by-count":84,"title":["Cytokines in psoriasis"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acc.2020.04.004_bb0010","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/bs.acc.2020.04.004_bb0015","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2020.04.004_bb0020","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2020.04.004_bb0025","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0030","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.rdc.2015.07.006","article-title":"Etiology and pathogenesis of psoriatic arthritis","volume":"41","author":"Barnas","year":"2015","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/bs.acc.2020.04.004_bb0035","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaad.2015.05.001","article-title":"Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis","volume":"73","author":"Villani","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0040","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1016\/bs.acc.2020.04.004_bb0045","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.molimm.2014.12.014","article-title":"Genetic and epigenetic basis of psoriasis pathogenesis","volume":"64","author":"Chandra","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.det.2014.09.001","article-title":"Genetics of psoriasis","volume":"33","author":"Mahil","year":"2015","journal-title":"Dermatol. Clin."},{"key":"10.1016\/bs.acc.2020.04.004_bb0055","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0065","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1038\/jid.2015.296","article-title":"Psoriasis in the US medicare population: prevalence, treatment, and factors associated with biologic use","volume":"135","author":"Takeshita","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0070","first-page":"519","article-title":"Psoriasis predisposition and occupational triggering factors in the appraisal of occupational medical expertises","volume":"12","author":"Mahler","year":"2014","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/bs.acc.2020.04.004_bb0075","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/jid.2011.262","article-title":"Human keratinocytes' response to injury upregulates CCL20 and other genes linking innate and adaptive immunity","volume":"132","author":"Kennedy-Crispin","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0080","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3390\/ijms18122684","article-title":"Molecular mechanisms and management of a cutaneous inflammatory disorder: psoriasis","volume":"18","author":"Woo","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.acc.2020.04.004_bb0085","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1346-8138.14139","article-title":"Pathogenesis of psoriasis and development of treatment","volume":"45","author":"Ogawa","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0090","first-page":"3573","article-title":"Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling","volume":"119","author":"Eyerich","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2020.04.004_bb0095","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4049\/jimmunol.1100123","article-title":"Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis","volume":"187","author":"Lin","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/eji.201344277","article-title":"Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA","volume":"45","author":"Lande","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.01.033","article-title":"Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis","volume":"136","author":"Mashiko","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2249.2012.04625.x","article-title":"Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality?","volume":"171","author":"Simoni","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0115","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1586\/1744666X.2014.894886","article-title":"The CXCL8\/IL-8 chemokine family and its receptors in inflammatory diseases","volume":"10","author":"Russo","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0120","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00441-014-1809-9","article-title":"Leukocyte recruitment in inflammation: basic concepts and new mechanistic insights based on new models and microscopic imaging technologies","volume":"355","author":"Leick","year":"2014","journal-title":"Cell Tissue Res."},{"key":"10.1016\/bs.acc.2020.04.004_bb0125","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ejcb.2010.04.008","article-title":"Interleukin-1, inflammasomes and the skin","volume":"89","author":"Feldmeyer","year":"2010","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0130","first-page":"1211","article-title":"Targeting the IL-1 family members in skin inflammation","volume":"11","author":"Jensen","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/bs.acc.2020.04.004_bb0135","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00403-013-1327-8","article-title":"Interleukin-1 family members are enhanced in psoriasis and suppressed by vitamin D and retinoic acid","volume":"305","author":"Balato","year":"2013","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/bs.acc.2020.04.004_bb0140","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.4049\/jimmunol.1003162","article-title":"IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression","volume":"186","author":"Johnston","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0145","doi-asserted-by":"crossref","first-page":"24S","DOI":"10.1111\/1523-1747.ep12505698","article-title":"Interleukin-1 in human skin: dysregulation in psoriasis","volume":"95","author":"Cooper","year":"1990","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0150","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/bjd.12355","article-title":"Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis","volume":"169","author":"Dowlatshahi","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0155","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjd.14685","article-title":"Successful response in a case of severe pustular psoriasis after interleukin-1\u03b2 inhibition","volume":"176","author":"Skendros","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0160","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/jid.2013.485","article-title":"Polymorphisms in IL-1B distinguish between psoriasis of early and late onset","volume":"134","author":"H\u00e9bert","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0165","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2230.2009.03704.x","article-title":"Serum cytokines and growth factor levels in Japanese patients with psoriasis","volume":"35","author":"Takahashi","year":"2010","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0170","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/exd.13139","article-title":"TNF-\u03b1 inhibitors reduce the pathological Th 1-Th 17\/Th 2 imbalance in cutaneous mesenchymal stem cells of psoriasis patients","volume":"26","author":"Campanati","year":"2017","journal-title":"Exp. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0175","article-title":"High levels of platelet-lymphocyte complexes in psoriasis patients are associated with a better response to anti-TNF-\u03b1 therapy","author":"Sanz-Mart\u00ednez","year":"2019","journal-title":"J. Invest. Dermatol."},{"issue":"Suppl 1","key":"10.1016\/bs.acc.2020.04.004_bb0180","first-page":"168","article-title":"Treatment of anti-TNF-related paradoxic palmoplantar psoriasis in Beh\u00e7et's disease with azathioprine","volume":"37","author":"Karadeniz","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0185","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.14309\/00000434-201710001-02017","article-title":"Anti-TNF alpha-induced psoriasis: a rare paradoxical side effect: 2016","volume":"112","author":"Shahid","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0190","article-title":"Psoriasis associated with tumor necrosis factor-alpha inhibitors in children with inflammatory diseases","author":"Buckley","year":"2019","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"10.1016\/bs.acc.2020.04.004_bb0195","first-page":"1","article-title":"A meta-analysis of the relationship between tumor necrosis factor-\u03b1 polymorphisms and psoriasis","author":"Wang","year":"2019","journal-title":"Dermatology"},{"key":"10.1016\/bs.acc.2020.04.004_bb0200","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jid.2016.11.022","article-title":"IL-6 differs from TNF-\u03b1: unpredicted clinical effects caused by IL-6 blockade in psoriasis","volume":"137","author":"Blauvelt","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/964069","article-title":"IL-6 as a druggable target in psoriasis: focus on pustular variants","volume":"2014","author":"Saggini","year":"2014","journal-title":"J. Immunol. Res."},{"key":"10.1016\/bs.acc.2020.04.004_bb0210","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2020.04.004_bb0215","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0065-2776(07)96002-2","article-title":"Regulation of interferon-gamma during innate and adaptive immune responses","volume":"96","author":"Schoenborn","year":"2007","journal-title":"Adv. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0220","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5455\/medarh.2018.72.410-413","article-title":"Serum concentrations of interferon gamma (IFN-\u03b3) in patients with psoriasis: correlation with clinical type and severity of the disease","volume":"72","author":"Kurtovic","year":"2018","journal-title":"Med. Arch."},{"key":"10.1016\/bs.acc.2020.04.004_bb0225","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/MI.2005.273","article-title":"Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity","volume":"2005","author":"Arican","year":"2005","journal-title":"Mediators Inflamm."},{"key":"10.1016\/bs.acc.2020.04.004_bb0230","first-page":"163","article-title":"Serum interferon-\u03b3 is a psoriasis severity and prognostic marker","volume":"84","author":"Abdallah","year":"2009","journal-title":"Cutis"},{"key":"10.1016\/bs.acc.2020.04.004_bb0235","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clim.2015.10.004","article-title":"Natural killer cells from psoriasis vulgaris patients have reduced levels of cytotoxicity associated degranulation and cytokine production","volume":"177","author":"Dunphy","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0240","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00011-019-01238-8","article-title":"Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors","volume":"68","author":"Cataldi","year":"2019","journal-title":"Inflamm. Res."},{"key":"10.1016\/bs.acc.2020.04.004_bb0245","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jdermsci.2018.07.001","article-title":"The distinct role and regulatory mechanism of IL-17 and IFN-\u03b3 in the initiation and development of plaque vs guttate psoriasis","volume":"92","author":"Yan","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/bs.acc.2020.04.004_bb0250","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/jid.2011.458","article-title":"A single intradermal injection of IFN-\u03b3 induces an inflammatory state in both non-lesional psoriatic and healthy skin","volume":"132","author":"Johnson-Huang","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0255","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0260","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cyto.2016.06.020","article-title":"Correlation of IL-12, IL-22, and IL-23 in patients with psoriasis and metabolic syndrome. Preliminary report","volume":"85","author":"Brito-Luna","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/bs.acc.2020.04.004_bb0265","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.4049\/jimmunol.177.7.4917","article-title":"An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12\/IL-23 in psoriasis","volume":"177","author":"Toichi","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0270","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamadermatol.2016.0751","article-title":"Therapeutic efficacy of interleukin 12\/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status","volume":"152","author":"Arakawa","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0275","doi-asserted-by":"crossref","first-page":"13466","DOI":"10.1038\/ncomms13466","article-title":"IL-12 protects from psoriasiform skin inflammation","volume":"7","author":"Kulig","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.acc.2020.04.004_bb0280","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","article-title":"Signaling and function of interleukin-2 in T lymphocytes","volume":"36","author":"Ross","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0285","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4103\/ijdvl.IJDVL_471_17","article-title":"Is there a correlation of serum and tissue T helper-1 and -2 cytokine profiles with psoriasis activity and severity? A cross-sectional study","volume":"84","author":"Khandpur","year":"2017","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0290","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s002960050111","article-title":"Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis","volume":"19","author":"Elkayam","year":"2000","journal-title":"Rheumatol. Int."},{"key":"10.1016\/bs.acc.2020.04.004_bb0295","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/ced.12251","article-title":"Differential expression of interleukin-2 by anti-CD3-stimulated peripheral blood mononuclear cells in patients with psoriatic arthritis and patients with cutaneous psoriasis","volume":"39","author":"Bos\u00e8","year":"2014","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0300","first-page":"208","article-title":"Polymorphisms in T helper 1 proinflammatory cytokine genes and the risk of psoriasis in a South Indian Tamil cohort","volume":"15","author":"Indhumathi","year":"2017","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/bs.acc.2020.04.004_bb0305","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5114\/ceji.2018.74873","article-title":"Association of the TNF-\u03b1, IL-2, and IL-2RB gene variants with susceptibility to psoriasis in a Turkish cohort","volume":"43","author":"Gulel","year":"2018","journal-title":"Cent. Eur. J. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0310","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11926-007-0075-1","article-title":"Pathophysiology of psoriasis: recent advances on IL-23 and TH17 cytokines","volume":"9","author":"Fitch","year":"2007","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/bs.acc.2020.04.004_bb0315","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature13199","article-title":"Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation","volume":"510","author":"Riol-Blanco","year":"2014","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2020.04.004_bb0320","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/1744666X.2017.1292137","article-title":"The role of IL 23 in the treatment of psoriasis","volume":"13","author":"Puig","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PTT.S98893","article-title":"Targeting IL-23 in psoriasis: current perspectives","volume":"8","author":"Fotiadou","year":"2018","journal-title":"Psoriasis"},{"key":"10.1016\/bs.acc.2020.04.004_bb0330","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/bs.acc.2020.04.004_bb0335","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.4049\/jimmunol.181.7.4733","article-title":"Induction of IL-17 + T cell trafficking and development by IFN-\u03b3: mechanism and pathological relevance in psoriasis","volume":"181","author":"Kryczek","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0340","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0345","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","article-title":"IL-17 receptor and its functional significance in psoriatic arthritis","volume":"359","author":"Raychaudhuri","year":"2012","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/bs.acc.2020.04.004_bb0350","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/bs.acc.2020.04.004_bb0355","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00403-012-1229-1","article-title":"Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis","volume":"304","author":"Yilmaz","year":"2012","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/bs.acc.2020.04.004_bb0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/819149","article-title":"Plaque-type psoriasis in Brazilian patients","volume":"2015","author":"de Oliveira","year":"2015","journal-title":"Mediators Inflamm."},{"key":"10.1016\/bs.acc.2020.04.004_bb0365","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2133.2012.10899.x","article-title":"Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis","volume":"167","author":"He","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0370","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/1744666X.2020.1679625","article-title":"Anti IL-17 in psoriasis","volume":"15","author":"Ly","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2019.01.013","article-title":"Clinical significance and immunobiology of IL-21 in autoimmunity","volume":"99","author":"Long","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/bs.acc.2020.04.004_bb0380","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/nm.1995","article-title":"Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis","volume":"15","author":"Caruso","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/bs.acc.2020.04.004_bb0385","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.4049\/jimmunol.1003326","article-title":"IL-21 promotes skin recruitment of CD4 + cells and drives IFN-\u03b3\u2013dependent epidermal hyperplasia","volume":"186","author":"Sarra","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2019.01865","article-title":"IL-21 induces an imbalance of Th17\/treg cells in moderate-to-severe plaque psoriasis patients","volume":"10","author":"Shi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0395","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10067-017-3862-8","article-title":"Autoantibodies against interleukin-21 correlate with disease activity in patients with rheumatoid arthritis","volume":"37","author":"Xing","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0400","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5962624","article-title":"Evaluating IL-21 as a potential therapeutic target in Crohn's disease","volume":"2018","author":"Holm","year":"2018","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/bs.acc.2020.04.004_bb0405","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0014-5793(92)80909-Z","article-title":"Interleukin-8, a chemotactic and inflammatory cytokine","volume":"307","author":"Baggiolini","year":"1992","journal-title":"FEBS Lett."},{"key":"10.1016\/bs.acc.2020.04.004_bb0410","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0923-1811(00)00167-5","article-title":"Interleukin-8-positive neutrophils in psoriasis","volume":"26","author":"Duan","year":"2001","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/bs.acc.2020.04.004_bb0415","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clim.2016.11.003","article-title":"Cyr61\/CCN1 is involved in the pathogenesis of psoriasis vulgaris via promoting IL-8 production by keratinocytes in a JNK\/NF-\u03baB pathway","volume":"174","author":"Wu","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0420","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1210\/en.2010-1481","article-title":"Visfatin enhances CXCL8, CXCL10, and CCL20 production in human keratinocytes","volume":"152","author":"Kanda","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/bs.acc.2020.04.004_bb0425","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/1756-185X.12444","article-title":"Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity","volume":"19","author":"Dikbas","year":"2016","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/bs.acc.2020.04.004_bb0430","doi-asserted-by":"crossref","first-page":"e655","DOI":"10.1097\/MJT.0000000000000330","article-title":"Effects of narrow band ultraviolet B on serum levels of vascular endothelial growth factor and Interleukin-8 in patients with psoriasis","volume":"23","author":"Chen","year":"2016","journal-title":"Am. J. Ther."},{"key":"10.1016\/bs.acc.2020.04.004_bb0435","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S1995-7645(14)60113-9","article-title":"Effect of Yinxieling decoction on PASI, TNF-\u03b1 and IL-8 in patients with psoriasis vulgaris","volume":"7","author":"Dai","year":"2014","journal-title":"Asian Pac. J. Trop. Med."},{"key":"10.1016\/bs.acc.2020.04.004_bb0440","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/jdv.12001","article-title":"Obesity, waist circumference, weight change and the risk of psoriasis in US women","volume":"27","author":"Kumar","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0445","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/jdv.15159","article-title":"Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study","volume":"33","author":"Fern\u00e1ndez-Armenteros","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0450","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-4632.2011.05270.x","article-title":"Association between obesity measured by different parameters and severity of psoriasis","volume":"52","author":"Duarte","year":"2013","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0455","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/ijd.13699","article-title":"Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction","volume":"56","author":"Lynch","year":"2017","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0460","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000481882","article-title":"Serum leptin, resistin, and adiponectin concentrations in psoriasis: a meta-analysis of observational studies","volume":"233","author":"Kyriakou","year":"2018","journal-title":"Dermatology"},{"key":"10.1016\/bs.acc.2020.04.004_bb0465","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/jdv.13701","article-title":"The triad psoriasis\u2013obesity\u2013adipokine profile","volume":"30","author":"Coimbra","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0470","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10238-019-00595-2","article-title":"Cell adhesion molecules, plasminogen activator inhibitor type 1, and metabolic syndrome in patients with psoriasis","volume":"20","author":"Teixeira","year":"2020","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/bs.acc.2020.04.004_bb0475","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/imr.12027","article-title":"IL-22, not simply a Th17 cytokine","volume":"252","author":"Rutz","year":"2013","journal-title":"Immunol. Rev."},{"key":"10.1016\/bs.acc.2020.04.004_bb0480","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00109-009-0457-0","article-title":"IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-\u03b3 are not","volume":"87","author":"Wolk","year":"2009","journal-title":"J. Mol. Med."},{"key":"10.1016\/bs.acc.2020.04.004_bb0485","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.4049\/jimmunol.1700021","article-title":"Limited presence of IL-22 binding protein, a natural IL-22 inhibitor, strengthens psoriatic skin inflammation","volume":"198","author":"Martin","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0490","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jaad.2017.05.017","article-title":"Skin-infiltrating, interleukin-22\u2013producing T cells differentiate pediatric psoriasis from adult psoriasis","volume":"77","author":"Cordoro","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0495","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1759720X17735756","article-title":"Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness","volume":"9","author":"Tsai","year":"2017","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/bs.acc.2020.04.004_bb0500","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1615\/CritRevImmunol.v32.i1.30","article-title":"Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease","volume":"32","author":"Iyer","year":"2012","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0505","doi-asserted-by":"crossref","first-page":"21795","DOI":"10.1073\/pnas.0911472106","article-title":"Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production","volume":"106","author":"Fujita","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.acc.2020.04.004_bb0510","first-page":"18","article-title":"The role of the TGF-\u03b2 family in wound healing, burns and scarring: a review","volume":"2","author":"Penn","year":"2012","journal-title":"Int. J. Burns Trauma"},{"key":"10.1016\/bs.acc.2020.04.004_bb0515","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.4049\/jimmunol.178.4.2018","article-title":"IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells","volume":"178","author":"Zheng","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0520","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/09629350310001619753","article-title":"Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity","volume":"12","author":"Jacob","year":"2003","journal-title":"Mediators Inflamm."},{"key":"10.1016\/bs.acc.2020.04.004_bb0525","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10238-017-0475-0","article-title":"Expression of MIF and TNFA in psoriatic arthritis: relationship with Th1\/Th2\/Th17 cytokine profiles and clinical variables","volume":"18","author":"Bautista-Herrera","year":"2018","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/bs.acc.2020.04.004_bb0530","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/09674845.2016.1207869","article-title":"Immunophenotyping of T cells in the peripheral circulation in psoriasis","volume":"73","author":"Priyadarssini","year":"2016","journal-title":"Br. J. Biomed. Sci."},{"key":"10.1016\/bs.acc.2020.04.004_bb0535","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.4049\/jimmunol.1401740","article-title":"IL-4 downregulates IL-1\u03b2 and IL-6 and induces GATA3 in psoriatic epidermal cells: route of action of a Th2 cytokine","volume":"195","author":"Onderdijk","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0540","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1073\/pnas.1416922112","article-title":"IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells","volume":"112","author":"Guenova","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.acc.2020.04.004_bb0545","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nm804","article-title":"Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease","volume":"9","author":"Ghoreschi","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/bs.acc.2020.04.004_bb0550","first-page":"133","article-title":"Immunomodulating treatment with low dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgaris","volume":"28","author":"Roberti","year":"2014","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/bs.acc.2020.04.004_bb0555","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jdermsci.2016.06.002","article-title":"Low dose cytokines reduce oxidative stress in primary lesional fibroblasts obtained from psoriatic patients","volume":"83","author":"Barygina","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/bs.acc.2020.04.004_bb0560","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/s41590-018-0256-2","article-title":"The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis","volume":"19","author":"Dainichi","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0565","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jdermsci.2017.07.003","article-title":"Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis","volume":"88","author":"Mashiko","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/bs.acc.2020.04.004_bb0570","first-page":"17","article-title":"The role of regulatory T cells and anti-inflammatory cytokines in psoriasis","volume":"27","author":"Owczarczyk-Saczonek","year":"2018","journal-title":"Acta Dermatovenerol. Alp. Pannonica Adriat."},{"key":"10.1016\/bs.acc.2020.04.004_bb0575","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jdermsci.2015.11.007","article-title":"Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3","volume":"81","author":"Yang","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/bs.acc.2020.04.004_bb0580","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-94-024-0921-5_5","article-title":"Regulation of cytokine gene expression in immunity and diseases","volume":"941","author":"Rutz","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0585","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1172\/JCI1476","article-title":"IL-10 is a key cytokine in psoriasis: proof of principle by IL-10 therapy: a new therapeutic approach","volume":"101","author":"Asadullah","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.acc.2020.04.004_bb0590","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.4049\/jimmunol.167.7.4075","article-title":"IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis","volume":"167","author":"McInnes","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0595","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s10875-012-9716-x","article-title":"Etanercept downregulates the Th17 pathway and decreases the IL-17+\/IL-10+ cell ratio in patients with psoriasis vulgaris","volume":"32","author":"Antiga","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0600","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.4049\/jimmunol.1602142","article-title":"Cutting edge: selective oral ROCK2 inhibitor reduces clinical scores in patients with psoriasis vulgaris and normalizes skin pathology via concurrent regulation of IL-17 and IL-10","volume":"198","author":"Zanin-Zhorov","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0605","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1006\/cyto.2002.1953","article-title":"Association between psoriasis severity and transforming growth factor beta(1) and beta (2) in plasma and scales from psoriatic lesions","volume":"19","author":"Flisiak","year":"2002","journal-title":"Cytokine"},{"key":"10.1016\/bs.acc.2020.04.004_bb0610","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1468-3083.2008.03064.x","article-title":"Serum and tissue expression of transforming growth factor beta 1 in psoriasis","volume":"23","author":"Zaher","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0615","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0923-1811(03)00107-5","article-title":"Downregulation of TGFbeta isoforms and their receptors contributes to keratinocyte hyperproliferation in psoriasis vulgaris","volume":"33","author":"Doi","year":"2003","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/bs.acc.2020.04.004_bb0620","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/bjd.15703","article-title":"Smad7 positively regulates keratinocyte proliferation in psoriasis","volume":"177","author":"Di Fusco","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0625","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/jmcb\/mjw012","article-title":"Adiponectin: a versatile player of innate immunity","volume":"8","author":"Luo","year":"2016","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0630","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/bph.14181","article-title":"Adipokines and inflammation: is it a question of weight?","volume":"175","author":"Francisco","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0635","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1089\/jir.2013.0078","article-title":"IL-6 and TNF-\u03b1 induced obesity-related inflammatory response through transcriptional regulation of miR-146b","volume":"34","author":"Shi","year":"2014","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/bs.acc.2020.04.004_bb0640","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","article-title":"Obesity in autoimmune diseases: not a passive bystander","volume":"13","author":"Versini","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/bs.acc.2020.04.004_bb0645","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0625.2010.01210.x","article-title":"Adipokines and psoriasis","volume":"20","author":"Gerdes","year":"2011","journal-title":"Exp. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0650","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1136\/annrheumdis-2012-202325","article-title":"Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity","volume":"72","author":"Eder","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/bs.acc.2020.04.004_bb0655","doi-asserted-by":"crossref","first-page":"101","DOI":"10.5114\/pdia.2014.40960","article-title":"Effect of psoriasis activity on serum adiponectin and leptin levels","volume":"32","author":"Baran","year":"2015","journal-title":"Adv. Dermatol. Allergol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0660","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/ijd.12706","article-title":"Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-\u03b1 inhibitors: results of a retrospective analysis","volume":"54","author":"Campanati","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0665","first-page":"13","article-title":"Serum visfatin, adiponectin, and tumor necrosis factor alpha (TNF-\u03b1) levels in patients with psoriasis and their correlation with disease severity","volume":"24","author":"Sereflican","year":"2016","journal-title":"Acta Dermatovenerol. Croat."},{"key":"10.1016\/bs.acc.2020.04.004_bb0670","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/bjd.17700","article-title":"Plasma levels of tumour necrosis factor-\u03b1 and adiponectin can differentiate patients with psoriatic arthritis from those with psoriasis","volume":"181","author":"Johnson","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0675","first-page":"1","article-title":"Adiponectin levels in a large pooled plaque psoriasis study population","author":"Gerdes","year":"2019","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/bs.acc.2020.04.004_bb0680","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12920-015-0115-z","article-title":"Defining \u201cmutation\u201d and \u201cpolymorphism\u201d in the era of personal genomics","volume":"8","author":"Karki","year":"2015","journal-title":"BMC Med. Genomics"},{"key":"10.1016\/bs.acc.2020.04.004_bb0685","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.gene.2018.09.042","article-title":"Genomic alterations driving psoriasis pathogenesis","volume":"683","author":"Singh","year":"2019","journal-title":"Gene"},{"key":"10.1016\/bs.acc.2020.04.004_bb0690","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CCID.S67534","article-title":"Targeting of interleukin-17 in the treatment of psoriasis","volume":"7","author":"Lonnberg","year":"2014","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0695","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1086\/503821","article-title":"Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene","volume":"78","author":"Nair","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/bs.acc.2020.04.004_bb0700","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.10935","article-title":"Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity","volume":"48","author":"Balding","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/bs.acc.2020.04.004_bb0705","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1038\/sj.jid.5700822","article-title":"TNF-alpha gene promoter -238G>A and -308G>A polymorphisms alter risk of psoriasis vulgaris: a meta-analysis","volume":"127","author":"Li","year":"2007","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0710","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03256427","article-title":"Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population","volume":"16","author":"Vasilopoulos","year":"2012","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/bs.acc.2020.04.004_bb0715","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5021\/ad.2015.27.2.128","article-title":"TNF, IL12B, and IFNG gene polymorphisms in Serbian patients with psoriasis","volume":"27","author":"Popadic","year":"2015","journal-title":"Ann. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0720","first-page":"GC01","article-title":"Profile of tumour necrosis factor alpha \u2212308 G\/A gene polymorphism in psoriatic patients in Karnataka, India","volume":"11","author":"Rajesh","year":"2017","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/bs.acc.2020.04.004_bb0725","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/FPC.0b013e32834e5e7b","article-title":"174G\/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-\u03b1 blockers","volume":"22","author":"Di Renzo","year":"2012","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/bs.acc.2020.04.004_bb0730","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.imlet.2013.09.028","article-title":"Genetic variations in IL6 and IL12B decreasing the risk for psoriasis","volume":"156","author":"Boca","year":"2013","journal-title":"Immunol. Lett."},{"key":"10.1016\/bs.acc.2020.04.004_bb0735","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjd.16083","article-title":"HLA-Cw6 and psoriasis","volume":"178","author":"Chen","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0740","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/exd.12577","article-title":"IL6 \u2212174G>C polymorphism is associated with an increased risk of psoriasis but not response to treatment","volume":"24","author":"Bia\u0142ecka","year":"2015","journal-title":"Exp. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0745","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s10067-016-3301-2","article-title":"Association of IL1\u0392 (\u2212511 A\/C) and IL6 (\u2212174 G\/C) polymorphisms with higher disease activity and clinical pattern of psoriatic arthritis","volume":"35","author":"Cubino","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0750","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s10067-015-3107-7","article-title":"Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis","volume":"34","author":"Schotte","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0755","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cyto.2014.01.008","article-title":"Polymorphisms in the TNF-\u03b1 and IL-10 gene promoters and risk of psoriasis and correlation with disease severity","volume":"66","author":"Karam","year":"2014","journal-title":"Cytokine"},{"key":"10.1016\/bs.acc.2020.04.004_bb0760","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/bjd.15363","article-title":"Interleukin-10 family cytokines pathway: genetic variants and psoriasis","volume":"176","author":"Galimova","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0765","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/iji.12407","article-title":"Interleukin 10 gene promoter polymorphisms (rs1800896, rs1800871 and rs1800872) and haplotypes are associated with the activity of systemic lupus erythematosus and IL10 levels in an Iranian population","volume":"46","author":"Mohammadi","year":"2019","journal-title":"Int. J. Immunogenet."},{"key":"10.1016\/bs.acc.2020.04.004_bb0770","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1582-4934.2008.00370.x","article-title":"Intron-1 rs3761548 is related to the defective transcription of Foxp3 in psoriasis through abrogating E47\/c-Myb binding","volume":"14","author":"Shen","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/bs.acc.2020.04.004_bb0775","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jdermsci.2009.09.010","article-title":"Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients","volume":"57","author":"Gao","year":"2010","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/bs.acc.2020.04.004_bb0780","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4103\/idoj.IDOJ_372_18","article-title":"Assessment of the possible role of FOXP3 gene (rs3761548) polymorphism in psoriasis vulgaris susceptibility and pathogenesis: Egyptian study","volume":"10","author":"Elsohafy","year":"2019","journal-title":"Indian Dermatol. Online J."},{"key":"10.1016\/bs.acc.2020.04.004_bb0785","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jdermsci.2009.05.004","article-title":"Extensive genetic polymorphism in the haplotype STR-TNF and HLA class I with the onset and evolution of psoriasis vulgaris","volume":"55","author":"Biral","year":"2009","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/bs.acc.2020.04.004_bb0790","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1365-4632.2010.04465.x","article-title":"Human leukocyte antigen (HLA) and single nucleotide polymorphisms (SNPs) tumor necrosis factor (TNF)-alpha \u2212238 and \u2212308 as genetic markers of susceptibility to psoriasis and severity of the disease in a long-term follow-up Brazilian study","volume":"49","author":"Magalh\u00e3es","year":"2010","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0795","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1111\/ijd.12894","article-title":"HLA-C and TNF gene polymorphisms are associated with psoriasis in Brazilian patients","volume":"55","author":"Cardili","year":"2016","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/bs.acc.2020.04.004_bb0800","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.mpmed.2017.03.010","article-title":"Psoriasis","volume":"45","author":"Higgins","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/bs.acc.2020.04.004_bb0805","unstructured":"Reddy SP, Shah V V, Lin EJ, Wu JJ. Etanercept. Elsevier; n.d. https:\/\/doi.org\/10.1016\/j.chtm.2016.07.033."},{"key":"10.1016\/bs.acc.2020.04.004_bb0810","unstructured":"Reddy SP, Lin EJ, Shah V V, Wu JJ. Adalimumab. Elsevier; n.d. https:\/\/doi.org\/10.1016\/j.chtm.2016.07.035."},{"key":"10.1016\/bs.acc.2020.04.004_bb0815","unstructured":"Ni C, Reddy SP, Wu JJ. Infliximab. Elsevier; n.d. https:\/\/doi.org\/10.1016\/j.chtm.2016.07.034."},{"key":"10.1016\/bs.acc.2020.04.004_bb0820","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.acc.2020.04.004_bb0825","unstructured":"Nia JK, Lebwohl MG. Ustekinumab. Elsevier; n.d. https:\/\/doi.org\/10.1016\/j.chtm.2016.07.036."},{"key":"10.1016\/bs.acc.2020.04.004_bb0830","series-title":"Targeting the IL-17\/IL-23 Axis in Chronic Inflammatory Immune-Mediated Diseases","author":"Tsoukas","year":"2015"},{"key":"10.1016\/bs.acc.2020.04.004_bb0835","first-page":"153","article-title":"Ixekizumab","author":"Reddy","year":"2016"},{"key":"10.1016\/bs.acc.2020.04.004_bb0840","first-page":"139","article-title":"Secukinumab","author":"Lin","year":"2016"},{"key":"10.1016\/bs.acc.2020.04.004_bb0845","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"391","author":"Deodhar","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2020.04.004_bb0850","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167757","article-title":"Anti-TNF-\u03b1 drugs differently affect the TNF\u03b1-sTNFR system and monocyte subsets in patients with psoriasis","volume":"11","author":"Gibellini","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2020.04.004_bb0855","unstructured":"Medicine NL of. ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/home (accessed February 5, 2020)."}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242320300391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242320300391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T19:39:30Z","timestamp":1758742770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242320300391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9780128239223"],"references-count":170,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2020.04.004","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}